COMP <GO>
CLPT vs TMCI // RETURN ON INVESTED CAPITAL (ROIC)
ClearPoint Neuro Inc. (NASDAQ) VS. Treace Medical Concepts Inc. (NASDAQ) • 15-METRIC TALLY: CLPT 3
— TMCI 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMCI
LAST: $10.67 (-0.19%) • MKT CAP: $342.7M
roic
-35.00%
LAST: $4.43 (-12.45%) • MKT CAP: $329.1M
roic
-32.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLPT VS. TMCI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLPT | TMCI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.40% | 79.80% | -18.40 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -32.40% | -2.60 | TMCI | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.13% | -8.96% | +1.83 | CLPT | /fcf-yield <GO> |
| Operating Margin | -60.00% | -25.50% | -34.50 | TMCI | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -27.70% | -32.30 | TMCI | /net-margins <GO> |
| Revenue Growth (YoY) | 17.80% | 1.60% | +16.20 | CLPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.90 | -0.70 | TMCI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 62.7 | -13.60 | TMCI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $342.7M | $329.1M | $13.6M | CLPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLPT REV | TMCI REV | CLPT GROSS % | TMCI GROSS % | CLPT FCF | TMCI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $37.0M | $212.7M | 61.4% | 79.8% | -$24.4M | -$29.5M |
| FY 2024 | $31.4M | $209.4M | 60.9% | 80.4% | -$9.2M | -$48.8M |
| FY 2023 | $24.0M | $187.1M | — | — | -$13.7M | -$34.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLPT // BETA —
TMCI // BETA —